OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
XERS
Xeris Biopharma Holdings, Inc.
XERS has a slight edge over OSCR overall, supported by lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XERS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
XERS's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XERS PE Valuation
XERS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XERS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for XERS, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XERS on earnings quality, reporting a profit while its opponent remains loss making.
XERS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.04 | +$0.05 |
| Q2 2026 | -$0.10 | +$0.10 |
| Q1 2026 | $0.07 | +$0.36 |
| Q4 2025 | $0.00 | +$0.37 |
| Q3 2025 | -$0.09 | +$0.36 |
| Q2 2025 | -$0.20 | +$0.23 |
| Q1 2025 | -$0.29 | +$0.18 |
| Q4 2024 | -$0.37 | +$0.08 |
XERS is still losing money, but far less than before: $0.04 per share over the past year, against $4.80 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XERS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
XERS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $107.2M | +44% |
| Q2 2026 | $92.1M | +29% |
| Q1 2026 | $83.1M | +38% |
| Q4 2025 | $85.8M | +43% |
| Q3 2025 | $74.4M | +37% |
| Q2 2025 | $71.5M | +49% |
| Q1 2025 | $60.1M | +48% |
| Q4 2024 | $60.1M | +35% |
XERS's revenue has grown year over year every quarter since late 2020: $107M last quarter, up 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +6.7 points |
| Q2 2026 | 5.6% | -0.6 points |
| Q1 2026 | 9.5% | +15 points |
| Q4 2025 | 20% | +17 points |
| Q3 2025 | 9.1% | +33 points |
| Q2 2025 | 6.3% | +23 points |
| Q1 2025 | -5.1% | +30 points |
| Q4 2024 | 2.8% | +25 points |
XERS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
XERS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.5M | +92% |
| Q2 2026 | $8.3M | +4440% |
| Q1 2026 | $9.9M | +$19.9M |
| Q4 2025 | $20M | +915% |
| Q3 2025 | $18.4M | +$26.7M |
| Q2 2025 | $182K | +$10.5M |
| Q1 2025 | -$10M | +$10.3M |
| Q4 2024 | $2M | -74% |
XERS has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XERS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +17.1M shares |
| 1 year | +6.9% | +12.3M shares |
| 3 years | +38% | +51.9M shares |
| 5 years | +186% | +124M shares |
| Available history | +603% | +163M shares |
XERS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | $365,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $63,000 |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over XERS on leverage, with a lower net debt burden relative to earnings.
XERS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 4.2x | High |
| Q3 2025 | 11.5x | High |
XERS's net debt is about 1.2 years of its operating earnings (EBITDA), down from 12 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XERS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 85.9 | Overbought |
| Stochastic | 93.8 | Overbought |
XERS's weekly RSI is 86 (overbought) and its Stochastic is 94 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XERS PE vs Healthcare Sector
| Metric | XERS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XERS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
XERS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 45% above |
| 20 week MA | $9.57 | 74% above |
| 50 week MA | $7.79 | 114% above |
| 100 week MA | $6.68 | 149% above |
| 200 week MA | $4.49 | 271% above |
XERS is in an uptrend: it's above all five of its weekly moving averages, and 271% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.
XERS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.45 | $5.45 | -27% |
| 2021 | $5.45 | $2.59 | -52% |
| 2022 | $2.59 | $1.26 | -51% |
| 2023 | $1.26 | $2.35 | +87% |
| 2024 | $2.35 | $3.43 | +46% |
| 2025 | $3.43 | $7.37 | +115% |
| 2026 YTD | $7.37 | $16.7 | +126% |
XERS has the edge over OSCR on returns for 2026, with the stronger performance.